The Mentor Corporation just announced that they just completed the first of three clinical phase trials with it’s prified botulinum Type A neurotox for the reduction of fown lines. This completed study involved over 400 test patients at ten different study sites in the US. These subjects received a single treatment with PurTox or a placebo.

The satisfaction with the outcome of treatments was measured using a standard global assessment tool and safety was assessed by adverse event tracking. A very large percentage of the test subjects expressed a high degree of satisfaction with their outcomes due to treatment with this new drug.

Source: Mentor Corporation